Crispr Therapeutics AG logo

Crispr Therapeutics AG (CRSP)

Market Closed
5 Dec, 20:00
NASDAQ (NMS) NASDAQ (NMS)
$
56. 88
-1.3
-2.23%
$
4.67B Market Cap
- P/E Ratio
0% Div Yield
1,583,749 Volume
-2.71 Eps
$ 58.18
Previous Close
Day Range
56.01 58.73
Year Range
30.04 78.48
Want to track CRSP and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 64 days
Cathie Wood's Buys And Rumors Aside, Here's Why Crispr Therapeutics Is A Strong Buy

Cathie Wood's Buys And Rumors Aside, Here's Why Crispr Therapeutics Is A Strong Buy

Crispr Therapeutics AG remains a Strong Buy, driven by forthcoming revenue following Casgevy's FDA/EMA approvals and a robust, expanding pipeline targeting high-value indications. CRSP's commercial launch of Casgevy is progressing, with their share of a $100M+ 2025 total revenue expectation, and significant growth expected into 2026. The pipeline's cardiovascular assets (CTX310/320) show promising early efficacy, with huge addressable markets and the potential to disrupt standard-of-care regimens.

Seekingalpha | 2 days ago
Meet the Beaten-Down Biotech Stock Cathie Wood Loves That Wall Street Says May Soar 50%

Meet the Beaten-Down Biotech Stock Cathie Wood Loves That Wall Street Says May Soar 50%

Cathie Wood aims to identify innovators and invest in them early in their stories. Wood has been regularly adding to her position in this stock, and it's one of her top holdings.

Fool | 6 days ago
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It

CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It

CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Zacks | 1 week ago
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know

CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know

Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.

Zacks | 3 weeks ago
CRISPR Therapeutics Post Q3 Earnings: Testing Investor Patience, But Still A Buy

CRISPR Therapeutics Post Q3 Earnings: Testing Investor Patience, But Still A Buy

CRISPR Therapeutics AG remains a pioneering gene editing company, with Casgevy's slow commercial ramp and robust pipeline driving long-term potential. Despite Casgevy's $2.2M list price and broad approvals, revenue growth is gradual due to complex treatment logistics and patient adoption hurdles. CRSP's pipeline includes promising in-vivo cardiovascular, CAR-T oncology/autoimmune, and diabetes programs, with key updates expected in 2025.

Seekingalpha | 3 weeks ago
CRSP Posts Narrower-Than-Expected Loss in Q3, Sales Miss Estimates

CRSP Posts Narrower-Than-Expected Loss in Q3, Sales Miss Estimates

CRISPR Therapeutics posts a narrower-than-expected Q3 loss, trims R&D spend, and advances late-stage and next-gen gene-editing programs.

Zacks | 3 weeks ago
CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Lags Revenue Estimates

CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Lags Revenue Estimates

CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $1.17 per share versus the Zacks Consensus Estimate of a loss of $1.32. This compares to a loss of $1.01 per share a year ago.

Zacks | 3 weeks ago
Should CRSP Stock Be in Your Portfolio Pre-Q3 Earnings?

Should CRSP Stock Be in Your Portfolio Pre-Q3 Earnings?

CRISPR Therapeutics is likely to witness an earnings beat as Casgevy sales climb and new CAR-T and in-vivo programs advance.

Zacks | 1 month ago
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It

CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It

Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.

Zacks | 1 month ago
CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Should You Buy?

CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Should You Buy?

CRISPR Therapeutics (CRSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks | 1 month ago
CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know

CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $74.89, moving 2.46% from the previous trading session.

Zacks | 1 month ago
CRISPR Therapeutics (CRSP) Surges 8.7%: Is This an Indication of Further Gains?

CRISPR Therapeutics (CRSP) Surges 8.7%: Is This an Indication of Further Gains?

CRISPR Therapeutics (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks | 1 month ago
Loading...
Load More